Cost Effectiveness Analysis

An economic analysis comparing the relative cost and impact of different medical treatments with the aim of directing health care spending more efficiently.

Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable With Increased Bevacizumab Reimbursement and Utilization

Jun. 13, 2020

David B. Glasser, Ravi Parikh, Flora Lum, George A. Williams

Abstract [from journal]

Purpose: To model Medicare Part B and patient savings associated with increased bevacizumab payment and utilization for intravitreal anti-vascular endothelial growth factor (VEGF) therapy.

Design: Cost analysis.

Methods: Medicare claims and IRIS® Registry data were used to calculate Medicare Part B expenditures and patient co-pays for anti-VEGF agents with increasing reimbursement and utilization of bevacizumab relative to ranibizumab and aflibercept.



Cost-Effectiveness of Mifepristone Pretreatment for the Medical Management of Nonviable Early Pregnancy: Secondary Analysis of a Randomized Clinical Trial

Mar. 2, 2020

Divyah Nagendra, Nathanael Koelper, Sandra E. Loza-Avalos, Sarita Sonalkar, Melissa Chen, Jessica Atrio, Courtney A. Schreiber, Heidi S. Harvie

Abstract [from journal]

Importance: Early pregnancy loss (EPL) is the most common complication of pregnancy. A multicenter randomized clinical trial compared 2 strategies for medical management and found that mifepristone pretreatment is 25% more effective than the standard of care, misoprostol alone. The cost of mifepristone may be a barrier to implementation of the regimen.

Objective: To assess the cost-effectiveness of medical management of EPL with mifepristone pretreatment plus misoprostol vs misoprostol alone in the United


Cost-Effectiveness Analysis in Pediatric Imaging: The Evidence (or Lack Thereof) Thus Far

Nov. 29, 2019

Hansel J. Otero, Andrew J. Degna, Nadja Kadom, Peter J. Neumann, Tara A. Lavelle

Abstract [from journal]

Objective: To systematically review all published cost-effectiveness analyses (CEAs) of imaging technologies in children.

Methods: We identified all CEAs involving fetal and pediatric imaging included in a publicly available repository of CEAs published since 1976. Information on publication characteristics, methods, costs, quality of life weights, and incremental cost-effectiveness ratios (ICERs) was recorded for each article.

Results: Of 480 diagnostic CEAs, only 10 focused on fetal


Cost-effectiveness of two opioid use disorder treatments

Dec. 18, 2018

[reposted from the CHERISH blog]

One key strategy in reducing deaths from the opioid epidemic is to improve access to existing evidence-based treatments. Two new economic studies by CHERISH Investigators Drs. Sean Murphy, Kathryn McCollister, and Bruce Schackman can help providers, patients, and payers sort through alternative pharmacotherapies to prevent opioid relapse.

Cost-Effectiveness Research in Anesthesiology

Nov. 2, 2018

Bijan J. Teja, Tori N. Sutherland, Sheila R. Barnett, Daniel S. Talmor

Abstract [from journal]

Perioperative interventions aimed at decreasing costs and improving outcomes have become increasingly popular in recent years. Anesthesiologists are often faced with a choice among different treatment strategies with little data available on the comparative cost-effectiveness. We performed a systematic review of the English language literature between 1980 and 2014 to identify cost-effectiveness analyses of anesthesiology and perioperative medicine interventions. We excluded interventions related to critical care or...

Cost-effective Screening and Treatment of Hepatitis C

Issue Brief
Sep. 17, 2018

In just five years, hepatitis C has changed from a difficult-to-treat chronic condition to one that is readily cured by a short course of medication. Medical breakthroughs have now created the possibility of eliminating the transmission of HCV, but also bring a new challenge for the health system—how to identify individuals carrying the hepatitis C virus (HCV), and how to pay for life-saving treatments. This Issue Brief reviews recent evidence on the cost-effectiveness of screening and treatment strategies, and makes the case for universal, one-time HCV screening for all US adults.

Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa

Dec. 14, 2017

Louise B.Russell, Sun-Young Kim, Ben Cosgriff, Sri Ram Pentakota, Stephanie J.Schrag, Ajoke Sobanjo-ter Meulen, Jennifer R.Verani, Anushua Sinha

Abstract [from journal] 

Background: A maternal group B streptococcal (GBS) vaccine could prevent neonatal sepsis and meningitis. Its cost-effectiveness in low-income sub-Saharan Africa, a high burden region, is unknown.

Methods: We used a decision tree model, with Markov nodes to project infants’ lifetimes, to compare maternal immunization delivered through routine antenatal care with no immunization. 37 countries were clustered on the basis of economic and health resources and past


Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States

Oct. 27, 2017

Sun-Young Kim, Chi Nguyen, Louise B.Russell, Sara Tomczyk, Fatimah Abdul-Hakeem, Stephanie J.Schrag, Jennifer R.Verani, Anushua Sinha

Abstract [from journal]

Background: In the U.S., intrapartum antibiotic prophylaxis (IAP) for pregnant women colonized with group B streptococcus (GBS) has reduced GBS disease in the first week of life (early-onset/EOGBS). Nonetheless, GBS remains a leading cause of neonatal sepsis, including 1000 late-onset (LOGBS) cases annually. A maternal vaccine under development could prevent EOGBS and LOGBS.

Methods: Using a decision-analytic model, we compared the public health impact, costs, and


The Value of Value Frameworks

Oct. 26, 2017

“Value” is more than a buzzword. In response to rising costs, payers, physicians, and patients have turned to value assessment frameworks to inform treatment plans and design sustainable budgets. However, the usefulness and potential of these tools remain murky. LDI’s 50th anniversary symposium convened a panel to elucidate key questions for the future of value frameworks—what does value mean to different stakeholders in the health care system? How should payers, doctors, and patients appraise the value of the care they receive?